An Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria

Summary

Open label extension study of Oxabact OC5 in patients with primary hyperoxaluria

Timeline

Start

2019-03-14

Primary completion

2021-07-14

Completion

2021-07-14

Outcome

Outcome not reported

Stopped: “Parent, pivotal study (OC5-DB-02) did not meet primary endpoint. No safety concerns for early termination.”

Drugs

Indications